Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating
Arcutis Biotherapeutics CFO Sells Shares Worth Over $110,000
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Arcutis Biotherapeutics (ARQT)
Express News | New Data Shows Zoryve® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
New Data Shows ZORYVE (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
Express News | Arcutis Biotherapeutics Inc - FDA Sets Pdufa Target Action Date of May 22, 2025
Express News | FDA Accepts Arcutis’ Supplemental New Drug Application for Zoryve® (Roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
FDA Accepts Arcutis' Supplemental New Drug Application for ZORYVE (Roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
Express News | Arcutis Announces Publication of Zoryve® (Roflumilast) Cream 0.15% Pivotal Results From Phase 3 Integument-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
Arcutis Announces Publication of ZORYVE (Roflumilast) Cream 0.15% Pivotal Results From Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $19
Buy Rating Affirmed for Arcutis Biotherapeutics Amid Positive Dermatology Market Signals
Rock Star Growth Puts Arcutis Biotherapeutics (NASDAQ:ARQT) In A Position To Use Debt
Insider Selling: Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Arcutis Completes Enrollment of Phase 1B Alopecia Areata Study Evaluating Arq-255
Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
Arcutis Biotherapeutics, Inc. (ARQT): This Small-Cap Healthcare Stock Is A Good Buy Right Now
Express News | Arcutis Biotherapeutics Inc -No New Safety Signals Observed During 56 Weeks of Treatment
Express News | Arcutis Biotherapeutics Inc: To Submit Snda to U.S. FDA in Q1 2025 for Roflumilast Cream 0.05%